Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Gastroenterology > DDW 2024 > Eosinophilic Oesophagitis Treatments and Outcomes > Dupilumab shows promising results in treating paediatric eosinophilic oesophagitis

Dupilumab shows promising results in treating paediatric eosinophilic oesophagitis

Presented by
Dr Puanani Hopson, Mayo Clinic, USA
Conference
DDW 2024
Doi
https://doi.org/10.55788/4fb7acbf
    Approved by the FDA in 2020 for patients aged 12 and older, dupilumab, a monoclonal antibody against the IL-4 receptor, has shown significant improvements in various histopathological parameters in paediatric eosinophilic oesophagitis (EoE).

    The study included 14 paediatric patients aged 4-19 years, diagnosed with EoE, whose oesophageal biopsies were analysed before and after dupilumab treatment [1]. Histologic remission was defined by a peak eosinophil count (PEC) of less than 15 on follow-up biopsy, assessed by a pathologist. The biopsies were evaluated using both traditional analysis by a pathologist and a validated AI model (Aiforia Technologies) for quantitative analysis of histopathologic features. The primary endpoints evaluated were PEC and EoE Histologic Scoring System (EoE-HSS) grade, assessing improvements in basal zone hyperplasia (BZH) and dilated intercellular spaces (DIS). Secondary endpoints included lymphocyte counts and the correlation of histologic changes with endoscopic reference scores (EREFS).

    The results were reported by Dr Puanani Hopson (Mayo Clinic, MN, USA) and her colleagues. Of the 14 participants, 10 achieved histologic remission, showing a median decrease of 79.3% in PEC and 93.4% in the average eosinophil count per 0.24 mm² by AI analysis. Reductions were also observed in BZH (56.7%) and DIS (45.6%) in those who achieved remission. Additionally, a 30.3% decrease in peak lymphocyte count was noted in patients in remission, while those not in remission showed a 20.4% increase. Correlation analysis for all participants indicated a moderate correlation (r=0.38) between EREFS changes and AI PEC changes and a weaker correlation (r=0.25) between EREFS changes and AI DIS changes.

    The study confirms that dupilumab improves EoE-related histologic findings in paediatric patients, with AI-based quantitative assessments providing results comparable with traditional pathologist’s evaluation. These findings highlight the potential of dupilumab as an efficacious treatment for EoE, offering a promising option for improving patient outcomes.


      1. Hopson P, et al. Quantitative assessment of dupilumab treatment in pediatric patients characterized by an artificial intelligence analysis of histopathologic features of eosinophilic esophagitis. Sa2054, DDW 2024, 18–21 May, Washington, DC USA.

    Copyright ©2024 Medicom Medical Publishers



    Posted on